Study of GIM-531 in advanced solid tumors
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new oral drug, GIM-531, alone and in combination with an anti-PD-1 therapy for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor (cancer that has spread or cannot be removed) and standard treatments have stopped working or are not available.
- You are able to do most daily activities (ECOG 0 or 1).
- You must be willing to provide a fresh tumor biopsy or have one taken within the past year.
- You must have measurable disease as seen on scans (per RECIST criteria).
- If you have brain metastases, they must be treated and stable for at least 4 weeks, and you must be on a low or no steroid dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IBI3005, given with other treatments, for people with advanced solid tumors that cannot be removed by surgery or have spread. It may help shrink tumors or slow their growth.
This trial tests an experimental drug called IBI3020 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for these patients.
This trial tests a new drug, GIM-122, in people with advanced solid tumors that have stopped responding to or cannot tolerate standard PD-1/PD-L1 inhibitors. The goal is to see if GIM-122 is safe and tolerable.
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
This study tests a combination of two investigational drugs (Simmitinib and SG001) in people with advanced solid tumors that have not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth, and to find the best dose for further studies.
This trial tests a new immunotherapy drug, GIGA-564, for people with advanced solid tumors that have not responded to or have returned after standard treatments. The goal is to see if the drug is safe and effective, and to find the best dose.
Hear when a new Melanoma Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.